From Scientific Progress to Commercial Strategy: Five Decisions for Growing Life Sciences Companies

Scientific progress and commercial strategy are different challenges

Strong science, validation and funding increase potential. They do not make the next commercial decision obvious.

The immediate priority could be partnership, licensing, investment, acquisition readiness, first adoption, market entry or validation of a repeatable commercial model.

Each of those outcomes requires different audiences, evidence, narratives and capabilities.

A company preparing for licensing will not engage the market like a diagnostics business building first customer adoption. A healthtech business navigating clinical and economic stakeholders will not use the same commercial system as a scientific consultancy building pipeline.

The strategy must begin with the next value-creation milestone, not with a list of marketing tactics.

That distinction protects the business from investing heavily in visibility or activity that is disconnected from the decisions it actually needs to influence.

Why “life sciences” does not have one go-to-market model

Life sciences describes a broad field rather than a single commercial model. For therapeutic biotech, value may be created through progress, validation, partnerships, licensing, investment and acquisition. Direct product commercialisation may be distant or never become the company’s own model.

Diagnostics, laboratory technology and scientific platforms may follow a more recognisable route involving customers, adoption, repeat purchase, expansion and partners.

Healthtech may need to influence clinical stakeholders, users, economic buyers, procurement, partners and investors.

Scientific services and consultancies may operate through a more conventional B2B model built around ICPs, demand generation, pipeline and sales.

This is not a complete taxonomy. It demonstrates a central principle: strategy must reflect how the individual business creates value.

Five commercial decisions for growing life sciences companies

The following decisions help leadership teams connect scientific progress with the next stage of enterprise and commercial value.

1. What value-creation milestone matters next?

The leadership team should begin by identifying the immediate strategic outcome around which the organisation needs to align.

Possible milestones include:

• a strategic partnership;
• a licensing agreement;
• the next investment round;
• acquisition or exit readiness;
• first commercial adoption;
• entry into a priority market;
• repeatable customer acquisition;
• validation of a commercial model;
• recruitment of critical leadership or scientific capability.

These are not interchangeable. Each has different implications for priorities and external engagement.

Partnership may require strategic relevance and confidence among a small number of potential partners. Customer adoption may require understanding the buying process, removing adoption barriers and creating a repeatable route to purchase. Investment may require a credible combination of progress, market potential, maturity and ability to execute.

The Growth Strategy should make this outcome explicit enough to guide the remaining decisions without pretending that longer-term possibilities no longer matter.

2. Which audiences can enable that milestone?

In a science-led business, an Ideal Customer Profile is not always a profile of an end customer.

The priority audience includes the organisations and stakeholder groups whose decisions can enable the immediate milestone.

Depending on the business, those audiences might include:

• pharmaceutical or licensing partners;
• strategic or institutional investors;
• potential acquirers;
• commercial customers and economic buyers;
• scientific collaborators;
• influential experts or key opinion leaders;
• senior hires;
• other strategic stakeholders.

Leadership should assess each audience in relation to the outcome it is trying to create.

How strategically relevant is the audience? Can the company access it? What evidence or relationships support engagement? How valuable could the outcome be? Will engagement create useful learning?

The purpose is still prioritisation: identify the organisations and people the business most needs to influence now.

3. What does each audience need to understand and believe?

Different stakeholders develop confidence in different ways.

A potential pharma partner, investor and senior scientific hire may all be interested in the same organisation, but not for the same reasons.

They may need confidence in:

• scientific or technical credibility;
• the relevance of the science;
• the strength of the opportunity;
• commercial potential;
• operational feasibility;
• leadership credibility;
• organisational maturity;
• the company’s ability to execute;
• evidence of progress.

Evidence requirements depend on the business, audience and context. Marketing strategy should not replace scientific, clinical or regulatory judgement. Its role is to present relevant evidence and messages coherently.

One generic message is rarely sufficient. Positioning should be consistent, while proposition and messaging interpret it for each stakeholder.

Positioning, corporate narrative and messaging connect what the organisation knows about itself with what another party needs to understand before it can act.

4. Does the company’s market presence support the strategy?

A sophisticated scientific proposition can be undermined by an unclear external presence. This is not about making the company “look good”; it is about supporting the value-creation strategy.

Positioning should clarify what the organisation should become known for and why it is relevant.

Brand should reflect quality, ambition and maturity without overstating progress.

The website should explain what the company does, why the science matters, where the opportunity lies and why the organisation is credible.

Content strategy should demonstrate scientific authority, understanding of the company’s niche, leadership thinking, evidence, progress and relevance.

Leadership visibility should give appropriate leaders a role in building confidence.

Not every company needs a rebrand or new website. The question is whether its market presence helps or hinders the audience decision the strategy depends on.

Where specialist brand or website implementation is required, Pathfinder can help establish the strategic brief and, where appropriate, coordinate suitable specialist partners. The strategic work should define what those assets need to achieve before execution begins.

5. What commercial capability and engagement model is needed now?

The next milestone should determine the capability the organisation builds.

That may involve the founder or CEO, business development, senior commercial or marketing leadership, internal marketing hires, content, PR and communications, specialist brand or website support, agencies, partners, and the systems needed to coordinate activity and evidence.

Not every capability must immediately be hired internally.

A company preparing for partnership conversations may need senior direction and narrative development more than a demand-generation team. A scientific services business with a proven proposition may need a conventional marketing and sales model.

A Fractional Marketing Director can be useful where the organisation needs senior marketing leadership and coordination before the scale or continuity of the role justifies a full-time appointment.

The decision is what capability is required now, what specialist support can provide and what can wait.

Simon spent 3+ years on BioStrata Marketing’s leadership team and as a strategist. That experience informs Pathfinder’s understanding of the commercial questions science-led organisations face; Pathfinder does not provide scientific, clinical or regulatory advice.

A practical prioritisation lens

Life sciences leadership teams often have several credible markets, applications, partnership routes or stakeholder groups available to them.

A practical prioritisation conversation can consider:

• importance to the next value-creation milestone;
• strategic fit with the company’s capabilities and ambition;
• strength of the supporting evidence;
• accessibility of the stakeholders involved;
• expected complexity and time to meaningful progress;
• commercial or enterprise-value potential;
• ability to create useful learning;
• resources and capability required.

This is a lens for leadership judgement, not an algorithm.

A score can create useful discipline, but it cannot decide how evidence quality, risk, timing and long-term optionality should be balanced. The objective is to make assumptions visible and trade-offs deliberate.

Building the go-to-market foundations

Before significant implementation begins, a robust strategy may need to establish a connected sequence:

Value-creation objective → Priority audiences and ICPs → Positioning → Value proposition → Audience-specific messaging → Strategic narrative → Go-to-market or engagement strategy → Content strategy → Capability requirements → Implementation roadmap

These are the commercial foundations for sustainable growth. They provide the strategic brief for downstream activity.

The sequence does not mean every element must be completed perfectly before external engagement. Activity should support a shared strategic logic and create evidence that improves it.

Early partner conversations may sharpen the proposition. Market engagement may reveal which evidence matters to commercial stakeholders. Strategy and learning should reinforce each other.

Common strategic mistakes

Keeping every option open can make the external proposition harder to understand and the organisation harder to mobilise.

Common mistakes include:

• treating every possible application as an immediate priority;
• assuming the target audience is always an end customer;
• leading with the technology rather than its relevance;
• using one message for every stakeholder;
• confusing scientific enthusiasm with commercial intent;
• having a sophisticated scientific story but an unclear corporate proposition;
• allowing the website and content to lag behind the maturity of the business;
• scaling marketing activity before agreeing commercial focus;
• making several hires without clear leadership or decision rights.

The answer is not to oversimplify the science. It is to establish an immediate pathway the organisation can explain, support and act upon.

From scientific progress to enterprise value

Commercial focus does not reduce the long-term potential of the science.

It creates a credible sequence for converting scientific progress into the next stage of enterprise value.

The objective is not necessarily to generate more leads. It is to ensure the business can identify the next value-creation milestone, understand the audiences that influence it, establish the proposition and evidence they require, and build the market presence and capability needed to move forward.

For funded companies making these choices while investment and expectations are increasing, After the Funding Round sets out five broader commercial priorities that help sequence resources before activity scales.

The Life Sciences Marketing Consultancy page explains how Pathfinder applies this commercial perspective to appropriate science-led organisations.

The specialist life sciences Growth Story shows one example of a more conventional services business building strategy and demand generation together.

The Growth Readiness Assessment offers a structured starting point for identifying which commercial capabilities most need attention. Used with leadership judgement, it can help turn a wide set of possible initiatives into a smaller number of connected priorities.